FDA sees no need for DCCR advisory committee meeting
The U.S. Food and Drug Administration (FDA) has decided that an advisory committee meeting is not needed at this point in the review process of Soleno Therapeutics‘ application seeking approval of its extended-release formulation of diazoxide choline (DCCR) to treat Prader-Willi syndrome (PWS). Soleno announced the regulatory update…